Cortex Pharmaceuticals Inc.: The Irvine developer of...

Cortex Pharmaceuticals Inc.: The Irvine developer of drugs for neurological and psychiatric disorders posted a net loss of $1.3 million, or 14 cents a share, for the first fiscal quarter ended Sept. 30, compared with a net loss of $1.2 million, or 16 cents a share, for the corresponding prior year period. No revenue was reported.